AngioDynamics Q4 2024 Earnings Report
Key Takeaways
AngioDynamics reported Q4 2024 net sales of $71.1 million, a 1.9% increase year-over-year. The company's Med Tech business saw an 11.3% increase, while the Med Device business decreased by 3.8%. The company achieved FDA 510(k) clearance and CE Mark approval for AlphaVac F18 System for the treatment of Pulmonary Embolism (PE).
Net sales increased by 1.9% to $71.1 million.
Med Tech net sales increased by 11.3% to $29.3 million.
Med Device net sales decreased by 3.8% to $41.8 million.
The company received FDA 510(k) clearance and CE Mark approval for AlphaVac F18 System for the treatment of Pulmonary Embolism (PE).
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Forward Guidance
For fiscal year 2025, the Company expects net sales to be in the range of $282 to $288 million, Med Tech net sales are expected to grow in the range of 10% to 12%, Med Device net sales are expected to grow in the range of 1% to 3%, gross margin to be approximately 52% to 53%, adjusted EBITDA loss of $2.5 million to $0, and adjusted loss per share in the range of $0.38 to $0.42.
Positive Outlook
- Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
- Med Tech net sales are expected to grow in the range of 10% to 12%
- Med Device net sales are expected to grow in the range of 1% to 3%
- Gross margin to be approximately 52% to 53%
- Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024
Challenges Ahead
- Adjusted EBITDA loss of $2.5 million to $0
- Adjusted loss per share in the range of $0.38 to $0.42
- Gross margin to be approximately 52% to 53%
- Med Device net sales are expected to grow in the range of 1% to 3%
- Med Tech net sales are expected to grow in the range of 10% to 12%
Revenue & Expenses
Visualization of income flow from segment revenue to net income